Cancer Therapy Advisor Staff

Researchers are conducting a phase 3 trial to compare Dato-DXd, with or without durvalumab, to investigator’s choice of treatment in patients with TNBC.

Researchers are comparing gedatolisib plus fulvestrant, with or without palbociclib, to standard treatment for HR+, HER2- advanced breast cancer.

Researchers are evaluating a cancer vaccine, AST-301, as adjuvant treatment for patients with HR-negative, HER2-low breast cancer.

Researchers are evaluating pembrolizumab plus investigator’s choice of chemotherapy in HR+, HER2-, locally recurrent inoperable or metastatic breast cancer.

Researchers are conducting a phase 3 trial to evaluate TOL2506, an extended-release formulation of leuprolide acetate, in patients with breast cancer.

Researchers are conducting a phase 1b/2 trial to compare various durvalumab-based combinations in patients with metastatic triple-negative breast cancer.